Literature DB >> 33953477

Giant cell myocarditis.

Naga Vaishnavi Gadela1, Anand Muthu Krishnan2, Osama Mukarram3, Nitya Sthalekar4.   

Abstract

Giant cell myocarditis (GCM) usually affects previously healthy adults and is a rapidly progressive and frequently fatal disease. It has a median survival of 3 months to death or transplant without appropriate therapy. Hence, early diagnosis is critical, with evidence showing rapidly instituted cyclosporine-based immunosuppression can improve transplant-free survival. Although transplant is an effective strategy, GCM can recur in 25% of transplanted hearts. We present a case of GCM in a patient who presented with conduction abnormalities and fulminant heart failure.
Copyright © 2021 Baylor University Medical Center.

Entities:  

Keywords:  Cardiomyopathy; giant cell myocarditis; heart transplantation; immunosuppressive regimen; ventricular arrhythmias

Year:  2021        PMID: 33953477      PMCID: PMC8059898          DOI: 10.1080/08998280.2021.1874775

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  11 in total

Review 1.  Giant Cell Myocarditis: A Brief Review.

Authors:  Jin Xu; Erin G Brooks
Journal:  Arch Pathol Lab Med       Date:  2016-12       Impact factor: 5.534

2.  Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators.

Authors:  L T Cooper; G J Berry; R Shabetai
Journal:  N Engl J Med       Date:  1997-06-26       Impact factor: 91.245

Review 3.  Giant cell myocarditis: diagnosis and treatment.

Authors:  L T Cooper
Journal:  Herz       Date:  2000-05       Impact factor: 1.443

4.  Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats.

Authors:  Y Okura; T Yamamoto; S Goto; T Inomata; S Hirono; H Hanawa; L Feng; C B Wilson; I Kihara; T Izumi; A Shibata; Y Aizawa; S Seki; T Abo
Journal:  J Mol Cell Cardiol       Date:  1997-02       Impact factor: 5.000

5.  Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression.

Authors:  Riina Kandolin; Jukka Lehtonen; Kaisa Salmenkivi; Anne Räisänen-Sokolowski; Jyri Lommi; Markku Kupari
Journal:  Circ Heart Fail       Date:  2012-11-13       Impact factor: 8.790

6.  Giant cell myocarditis in a 12-year-old girl with common variable immunodeficiency.

Authors:  Helmut Laufs; Peter Andrija Nigrovic; Lynda C Schneider; Hans Oettgen; Nido Pedro Del; Ivan P G Moskowitz; Elizabeth Blume; Antonio R Perez-Atayde
Journal:  Mayo Clin Proc       Date:  2002-01       Impact factor: 7.616

7.  A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction.

Authors:  M Kodama; Y Matsumoto; M Fujiwara; F Masani; T Izumi; A Shibata
Journal:  Clin Immunol Immunopathol       Date:  1990-11

8.  Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis.

Authors:  Joseph J Maleszewski; Victor M Orellana; David O Hodge; Uwe Kuhl; Heinz-Peter Schultheiss; Leslie T Cooper
Journal:  Am J Cardiol       Date:  2015-03-24       Impact factor: 2.778

9.  A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis.

Authors:  Yuji Okura; G William Dec; Joshua M Hare; Makoto Kodama; Gerald J Berry; Henry D Tazelaar; Kent R Bailey; Leslie T Cooper
Journal:  J Am Coll Cardiol       Date:  2003-01-15       Impact factor: 24.094

10.  Anti-alpha beta T cell receptor antibody prevents the progression of experimental autoimmune myocarditis.

Authors:  H Hanawa; M Kodama; T Inomata; T Izumi; A Shibata; M Tuchida; Y Matsumoto; T Abo
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.